Koninklijke Philips N.V. reported strong financial results for 2023, achieving EUR 18.2 billion in sales, while also agreeing with the FDA on a consent decree concerning Philips Respironics operations in the US, which will affect their product sales moving forward. Their profitability improved, with adjusted EBITA margins at 10.5% for the year, despite a EUR 363 million provision related to the consent decree.